| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif. – November 3, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2026, and provided business highlights. |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif. – August 6, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2026, and provided business highlights. |
| 28 Jul 2026 |
8-K: Completion of Acquisition or Disposition of Assets
On July 27, 2026, Denali Therapeutics Inc. (the “Company”) completed the previously disclosed sale (the “Sale”) of its Rare Pediatric Disease Priority Review Voucher (the “PRV”) to a large pharmaceutical company. The Company received the... |
| 18 Jun 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
SOUTH SAN FRANCISCO, Calif., – June 18, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today announced it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $195... |
| 04 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 3, 2026, Denali Therapeutics Inc. (the “Company”) held its annual meeting of stockholders. Of the 158,675,498 shares of common stock outstanding as of April 9, 2026, the record date for the meeting, 137,986,127 shares of common s... |
| 22 May 2026 |
8-K: Regulation FD Disclosure
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., – May 7, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2026, and provided business highlights, including the recent U.S. Food and Drug A... |
| 03 Apr 2026 |
8-K: Termination of a Material Definitive Agreement
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN) |
| 31 Mar 2026 |
8-K: Creation of a Direct Financial Obligation; Regulation FD Disclosure
The information contained in Item 1.01 of the Form 8-K filed by Denali Therapeutics Inc. (the “Company”) on December 4, 2025 related to the synthetic royalty funding agreement between the Company and Royalty Pharma (the “Royalty Agreemen... |
| 25 Mar 2026 |
8-K: Regulation FD Disclosure
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., – February 26, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business highlights. |
| 06 Jan 2026 |
8-K: Regulation FD Disclosure
Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome |
| 10 Dec 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
As representatives (the “Representatives”) of the several Underwriters |
| 04 Dec 2025 |
8-K: Regulation FD Disclosure; Other Events
1 Welcome to Denali Therapeutics 2025 Investor Day December 4, 2025 Exhibit 99.1 |
| 04 Dec 2025 |
8-K: Entry into a Material Definitive Agreement
SOUTH SAN FRANCISCO, Calif. and NEW YORK, N.Y. — December 4, 2025 — Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sale... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., – November 6, 2025 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2025, and provided business highlights. |
| 14 Oct 2025 |
8-K: Regulation FD Disclosure
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome) |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., – August 11, 2025 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the second quarter ended June 30, 2025, and provided business highlights. |
| 07 Jul 2025 |
8-K: Regulation FD Disclosure
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II) |
| 03 Jun 2025 |
8-K: Entry into a Material Definitive Agreement; Submission of Matters to a Vote of Security Holders
This Registration Rights Agreement (this “Agreement”) is made as of June 3, 2025 by and between Denali Therapeutics Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to th... |
Loading...